Xencor was one of ESMO clearest winners. Early stage data for XmAb819, its double targeted antibody for kidney cancer, showed a 46 percent response rate at the highest dose tested in patients whose disease had progressed after several previous treatments. RBC Capital Markets analyst Leonid Timashev wrote the data exceeded the efficacy bar going in, and Leerink called the presentation one of the meeting best datasets, with side effects the main reservation. Xencor plans a Phase 3 trial in third line patients against Aveo Oncology Fotivda.
Enanta Pharmaceuticals is changing chief executive after 23 years. Jay Luly, age 70, will retire as president and chief executive by February 1, 2027, and will stay on as a strategic adviser through the rest of 2027. The board has begun a search covering internal and external candidates. Tara Kieffer, previously chief product strategy officer, was appointed to the newly created role of chief operating officer. Enanta is a clinical stage company working on small molecule drugs for viral infections and immunological diseases, including hepatitis C follow on work and respiratory syncytial virus.
Sanofi European pricing strategy was reported by Endpoints News on October 30 as seeking higher drug prices in Europe rather than withholding product launches under its United States pricing deal with the Trump administration. That claim is single sourced in this edition: no second independent outlet confirming the specific position was found in targeted searches in this run, so it is carried here as a reported position to watch, not as a confirmed policy, and readers should treat it at evidence grade C. It is consistent in direction with the public most favoured nation framework, under which Sanofi agreed to align some United States Medicaid prices with other high income countries, but consistency is not corroboration.
Gene editing pioneer David Liu used the European Society of Gene and Cell Therapy congress in Hamburg to argue for disease agnostic editing approaches, in Genetic Engineering and Biotechnology News coverage of the meeting. The remarks are a field signal rather than a data release: the push is toward platform methods that can be retargeted across diseases, which is the same direction as the FDA individualised gene editing guidance covered in this beat on October 28.
In preclinical work, Genetic Engineering and Biotechnology News reported that blocking a protein slowed pancreatic tumour growth and reduced immune suppression in mice. Mouse data of this kind are hypothesis generating only and carry no implication for human dosing or timelines, and the item is recorded here for completeness rather than as a development candidate.
Two small filings from the SEC pool are worth noting. Annovis Bio disclosed that on October 29 it received a New York Stock Exchange notice that it is no longer in compliance with the continued listing standard in Section 802.01B of the Listed Company Manual. Northwest Biotherapeutics disclosed a commercial loan agreement dated October 26 with Streeterville Capital for 5,505,000 dollars, with a 22 month maturity and no repayments for the first eight months. Neither filing changes a clinical programme, but both bear on how long each company can fund the programme it has.
Leadership movement elsewhere in the sector included the chief executive of the shut down Be Bio moving to Orbis, in Endpoints News reporting of sector appointments on October 30. The item is headline level only in this edition and is not relied on for any figure.